Tereau Daniel R 4
4 · PERKINELMER INC · Filed Mar 22, 2023
Insider Transaction Report
Form 4
Tereau Daniel R
Please See Remarks
Transactions
- Sale
Common Stock
2023-03-20$124.79/sh−300$37,437→ 11,611 total - Exercise/Conversion
NQ Stock Option (right to buy)
2023-03-20−3,750→ 0 totalExercise: $52.65Exp: 2024-02-07→ Common Stock (3,750 underlying) - Sale
Common Stock
2023-03-20$121.69/sh−15$1,825→ 22,337 total - Sale
Common Stock
2023-03-20$123.37/sh−5,122$631,901→ 17,215 total - Exercise/Conversion
Common Stock
2023-03-20$52.65/sh+3,750$197,438→ 22,352 total - Sale
Common Stock
2023-03-20$124.01/sh−5,304$657,749→ 11,911 total
Footnotes (7)
- [F1]The Exercise Price included on the Form 4 filed on February 8, 2017 for the Reporting Person was incorrectly reported due to administrative error.
- [F2]The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by Mr. Tereau on February 16, 2023.
- [F3]The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $121.66 to $121.74. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $122.74 to $123.72. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $123.74 to $124.73. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F6]The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $124.74 to $124.81. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
- [F7]This option became exercisable in three equal annual installments beginning on February 7, 2018, which was the first anniversary of the date on which the option was granted.